Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KI-3119
- Development stage
- Preclinical
- Lead developer
- Kuhnil Pharmaceutical
- Modality
- Small Molecules
01
Overview
KI-3119 is a small molecule drug candidate being developed by Kuhnil Pharmaceuticals for the treatment of hyperlipidemia. As of early 2024, the compound is in the preclinical stage of development. Hyperlipidemia is a condition characterized by abnormally elevated levels of lipids, such as cholesterol and triglycerides, in the blood, which increases the risk of cardiovascular disease. While the specific biological target and mechanism of action for KI-3119 have not been publicly disclosed by the developer, it is part of a broader pipeline of lipid-lowering agents aimed at managing metabolic and cardiovascular health.
Beyond the preview
Go deeper on KI-3119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KI-3119.